FDA Warns RonanRx Over American-Made GLP-1 Claims

The U.S. Food and Drug Administration (FDA) has warned RonanRx, Inc., a telehealth seller of compounded semaglutide and tirzepatide based in Elgin, Texas, that a promotional video calling its weight-loss drugs “American made” and “farm-to-table drugs” misled patients about where the medicine comes from. In a warning letter dated October 30, 2026, the agency said its records show no FDA-registered U.S. facility listed as the manufacturer of either drug’s active ingredient for compounding.

The letter, signed by Clint L. Narver, director of the Office of Compounding Quality and Compliance in FDA’s Center for Drug Evaluation and Research, also faults RonanRx’s website for suggesting the drugs were FDA approved and its product photos for implying RonanRx compounded them itself. RonanRx has 15 working days from receipt to respond.

A flag, confetti and a $78 price

The origin claim gets the longest passage in the letter. FDA describes a video reposted and pinned at the top of the company’s feed on X, under the handle @Ronan_Rx. In it, a speaker offers “drugs like Ozempic” for “seventy-eight dollars a month,” asks whether the drugs are legit and answers with a bleeped “super legit.” The video calls the products “American made” and “farm-to-table drugs,” then closes on confetti bursting around an American flag while two people in sterile garments dance in front of it.

FDA said that combination conceals the true origin of the products and creates “the misleading impression that your products have a domestic origin indicative of superior quality.” Because the agency found no drug listing naming a U.S. establishment as the maker of semaglutide or tirzepatide active pharmaceutical ingredient intended for compounding, it concluded the ingredient in RonanRx’s products was not made in the United States.

The finding matters beyond one company. A compounder in the United States can mix, fill and label a drug domestically while the active ingredient arrives from abroad. In this letter, FDA treated a domestic-origin pitch for the finished product as misbranding because the ingredient itself, by the agency’s records, was made elsewhere.

Two disclaimers that did not help

The letter quotes two category headings from the RonanRx website. One read “Well-Studied Compounded Medications,” described as drugs “with substantial human clinical evidence” that “may not itself be FDA-approved.” The other read “FDA-Approved Compounded Medications,” described as drugs “whose active ingredient has at least one FDA-approved branded form for the indication described.”

Compounded drugs are not FDA approved, and FDA said the hedges attached to those headings, along with a separate statement that compounded medications are not FDA approved, “do not cure the misleading overall impression.” The agency also cited the X profile line “Explore GLP-1s like Ozempic” and product photos showing “RonanRx” on the pictured label, which it said suggested RonanRx was the compounder “when in fact it is not.”

The same claims FDA has flagged all year

RonanRx joins a long list. FDA announced 30 warning letters to telehealth companies on March 3, 2026, citing claims of sameness with approved drugs and labels carrying the telehealth brand’s name. Bloomberg Law reported that the agency posted another 25 on June 16. EC4IM covered the March round in FDA Warns 30 Telehealth Firms Over Compounded GLP-1 Marketing Claims.

FDA’s standing guidance page, FDA to Telehealth Companies, lists five claim types the agency objects to: branding that implies the telehealth company is the compounder, calling a compounded drug a generic or the same as an approved drug, claiming FDA approval or review, claiming clinically proven equal results, and describing a pharmacy or outsourcing facility as FDA approved or licensed. The RonanRx letter touches the first and third. Product origin is not on that list.

What FDA asked RonanRx to produce

The response FDA requested is specific. RonanRx must identify the entities that actually produce the compounded drugs offered on its website, send a representative sample of their labeling, and either fix or show it has removed the false or misleading claims. A footnote tells the company to reassess advertising “across all platforms, including television and social media.”

Those three items are also a practical audit list for other GLP-1 telehealth brands. A site that cannot name its dispensing pharmacy on the product page, or that shows its own logo on a vial it did not fill, is using the same pattern FDA cited here. EC4IM has looked at that disclosure question before in GLP-1 Telehealth Sellers Face Patients Told to Check the Dispensing Pharmacy First.

Copy to check on product pages, ads and checkout

Origin language. “American made,” “made in the USA,” “domestic” or flag imagery applied to a compounded GLP-1 now carries risk unless the active ingredient’s source supports it.
Approval language. Section names, filters and comparison charts that pair “FDA-approved” with “compounded” drew a citation even with a disclaimer underneath.
Brand-name comparisons. Phrases such as “GLP-1s like Ozempic” in bios, ad headlines and checkout summaries were quoted as misleading.
Vial and box photos. Images that show the telehealth brand on the label suggest the brand compounded the drug.
Reposted video. FDA treated a reposted and pinned clip as the company’s own promotion.

A telehealth program applying for card acceptance through a specialty provider such as Organic Payment Gateways may have its live site and social accounts reviewed during underwriting, and a pinned video or a product category titled “FDA-Approved Compounded Medications” is the kind of content that review can turn up.

What is still unknown

The letter does not say which pharmacy compounds RonanRx’s products or where the active ingredient is made, only that FDA’s records list no U.S. manufacturer. A warning letter is FDA’s statement of alleged violations, not a court finding, and the company can contest it in its response. FDA warned that failing to correct the violations “may result in legal action without further notice, including, without limitation, seizure and injunction.”

Origin claims join the GLP-1 marketing list

FDA’s October 30 letter to RonanRx repeats familiar objections about implied approval and branded labels, but it also says a compounded GLP-1 cannot be sold as “American made” when the active ingredient is not made in the United States. For telehealth sellers, origin claims now sit beside the approval, sameness and compounder-branding language FDA has cited in earlier letters, and the agency applied all of it to a reposted video as readily as to the website.

FDA Warns RonanRx Over American-Made Claims for Compounded GLP-1s